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This study investigates the association of microsatellite
polymorphisms in XRCC1, XRCC3 and XRCC5 with the de-
velopment of late radiation-induced radiotherapy reactions
and examines the correlation between these microsatellites
and cancer incidence. Sixty-two women with cervical or en-
dometrial cancer treated with radiotherapy were included in
the study. According to the CTCAEv3.0 scale, 22 patients
showed late adverse radiotherapy reactions (grade 2 or more).
PCR on lymphocyte DNA followed by automated fragment
analysis was performed to examine the number of tandem
repeat units at each locus. No significant association was found
between the repeat length at any of the microsatellites in
XRCC1, XRCC3 or XRCC5 and the incidence of late radio-
therapy complications. Since higher odds ratios (ORs) were
found for the rare XRCC1 [AC]11 and [AC]21 repeats (OR 5
2.65, P 5 0.325 and OR 5 8.67, P 5 0.093, respectively), the
possible involvement of these small and large repeats in clin-
ical radiosensitivity cannot be completely ruled out. When
specific numbers of repeats were examined, no significant cor-
relation was found between the microsatellite repeat length in
XRCC1 and XRCC5 and cancer incidence. A weak correlation
between XRCC3 [AC]16 homozygotes and cancer incidence
was found (OR 5 2.56, P 5 0.055). A large-scale multicenter
study of cancer patients with a high number of radiosensitive
individuals is needed to clarify the value of rare polymorphic
microsatellite repeats in XRCC1 and XRCC3 as a biomarker
of clinical radiosensitivity or increased cancer risk. q 2005 by
Radiation Research Society
INTRODUCTION
In radiation oncology, radiation dose protocols are de-
pendent on both the tolerance of healthy tissue and the
1 Address for correspondence: Department of Anatomy, Embryology,
Histology and Medical Physics, Proeftuinstraat 86, B-9000 Gent, Bel-
gium; e-mail: kim.deruyck@UGent.be.
tumor control probability. In a small percentage of patients,
radiation doses that are usually well tolerated by the healthy
tissues within the irradiation field result in unexpected acute
and/or late radiotoxic effects. The development of predic-
tive methods to determine the degree of radiosensitivity of
both tumor and healthy tissue has become of major interest
in radiobiological research (1).
Several observations indicate that normal tissue hyper-
sensitivity may be related to genetic factors (2, 3). Several
studies have reported a possible correlation between genetic
polymorphisms and adverse radiotherapy reactions in pa-
tients (4–12). Although most studies have not detected a
conclusive correlation between genotype and clinical radio-
sensitivity, Price et al. have reported a highly significant
association between clinical radiosensitivity and rare mi-
crosatellites (unusually large or unusually small alleles) in
the DNA repair genes XRCC1 and XRCC3 (13).
Microsatellites are tandemly repeated highly polymor-
phic sequences and are common throughout the human ge-
nome. Repeat units are gained and lost by DNA replication
slippage, a mutation mechanism that results from the tran-
sient dissociation of the replicating DNA strands followed
by misaligned reassociation (14, 15). Expansions of triplet
repeats are the underlying cause of several genetic diseases
such as myotonic dystrophy, Huntington’s disease and frag-
ile X syndrome (16–18). Furthermore, microsatellites are
the molecular targets for malfunctioning repair and repli-
cation proteins in diseases such as hereditary non-polyposis
colorectal carcinoma (HNPCC), where there is a defect in
mismatch repair, and Bloom’s syndrome, where a DNA he-
licase homologue is defective (19, 20).
XRCC1 plays an important role in the base excision re-
pair pathway (BER) and participates as a scaffolding inter-
mediate by interacting with ligase III, DNA polymerase b
and poly(ADP-ribose) polymerase (21). XRCC3 functions
in the homologous recombination repair pathway (HHR) by
repairing double-strand breaks. XRCC5 or Ku80 is in-
volved in the non-homologous end-joining repair pathway
(NHEJ), and encodes, together with the G22P1 (KU70) and
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PRKDC genes, components of a DNA-dependent protein
kinase (DNA-PK) (22).
In present study we investigated whether polymorphic
microsatellites in three DNA repair genes, XRCC1, XRCC3
and XRCC5, are associated with clinical radiosensitivity
and cancer incidence. To this end we have screened for
these microsatellites in patients with cervical or endome-
trial cancer who received radiotherapy treatment and in a
control population of healthy individuals.
MATERIALS AND METHODS
Participants
The patient group has been described previously (12). Sixty-two wom-
en with cancer of the cervix (n 5 30) or endometrium (n 5 32) were
treated with fractionated external-beam radiotherapy to the pelvis (one
anterior and two lateral fields, 25 MV photons) followed by a brachy-
therapy boost at the Ghent University Hospital. Fifteen patients received
a tumor dose of 45 Gy (25 3 1.8 Gy), 22 patients received a tumor dose
of 46 Gy (23 3 2 Gy), and 22 patients received a tumor dose of 50 Gy
(25 3 2 Gy). Three patients received 46 Gy supplemented with a para-
metrial boost up to 60 Gy. Except for two patients, all patients were
additionally treated by brachytherapy using either vaginal ovoids, Fletch-
er-type applications, or perineal implants. All brachytherapy was per-
formed using a pulsed dose-rate technique with iridium-192. Total doses
from brachytherapy ranged from 15 to 35 Gy (dose rate 0.5 to 0.65 Gy/
h). Eighteen patients with cancer of the cervix received combined radio-
chemotherapy and were treated with 40 mg/m2 cisplatinum per week dur-
ing the period of the external radiotherapy. Forty-six patients were op-
eratively treated with a Wertheim Meigs hysterectomy. Nine premeno-
pausal patients received hormone replacement therapy (estrogen). The
mean age of the patients at the time of treatment was 59 years (range
24–80 years).
All patients have been scored with respect to several different normal
tissue reactions by the same oncologist according to the Common Ter-
minology Criteria for Adverse Events (CTCAE) scale version3.0 of the
National Cancer Institute (23). Forty patients showed no or very light
reactions to radiotherapy (CTC0–1), 14 patients experienced intermediate
but distinct radiotherapy reactions (CTC2), six patients showed severe
radiotherapy reactions (CTC3), one patient experienced life-threatening
radiotherapy reactions (CTC4), and one patient died as a consequence of
the radiotherapy (CTC5). Complication specifications are described in
more detail by De Ruyck et al. (12). All normal-tissue reactions appeared
6 months to 5.7 years after radiotherapy and can be considered as late
reactions. The mean time of follow-up was 4.8 years (range 0.7–10.6
years). Patients classified in CTC0–1 are indicated as nonradiosensitive
patients, while patients classified in CTC2, CTC3, CTC4 and CTC5
(CTC21) are indicated as radiosensitive patients. For these two patient
groups under study, age at time of treatment and follow-up period were
very similar. Mean age at the end of the last radiation treatment for the
patients without adverse reactions (CTC0–1) was 57 years and for the
patients with adverse reactions (CTC21) 62 years, while the mean fol-
low-up time for the two groups was 5.0 and 4.5 years, respectively.
A Caucasian control population of 118 cancer-free individuals was
used to determine the overall population microsatellite frequency and
allows association analysis of microsatellite genotype with cancer inci-
dence. The control individuals were employees of the Ghent University
Hospital and were recruited during the annual occupational medical ex-
amination. The mean age of controls was 38 years (range 22–62 years).
The patient and the control populations were ethnically matched. All
individuals were Belgian. The mean age of the patients was higher in
comparison with the healthy controls, 59 years and 38 years, respectively.
However, there are no indications that microsatellite frequencies at the
loci considered vary with age. The healthy control population consisted
of 53 men and 65 women, while the patients are all women. This lack
of sex matching should not cause a problem since the loci studied are
located on autosomes. Moreover, x2 tests on the control population ver-
ified that there are no differences between microsatellite frequencies in
men and women (0.16 , P , 0.96 for all repeats tested separately in
the three XRCC genes).
A heparinized blood sample was taken from each individual in the
study, and lymphocytes were isolated and frozen for genotyping analysis.
The study was approved by the Ghent University Hospital Ethical Com-
mittee. All participants received oral and written information concerning
the study and signed the informed consent form.
Genotyping Analysis
Genomic DNA was extracted from isolated lymphocytes, and DNA
analysis was successful on all samples. A [AC]n microsatellite repeat
region in the 39 untranslated region (39 UTR) of XRCC1 (accession num-
ber L34079), a [AC]n microsatellite repeat located in intron 3 of XRCC3
(accession number AF000735), and a [GAPyA]n repeat located 120kb 59
of XRCC5 (accession number AF000736) were analyzed. The repeat re-
gions were amplified by PCR, and sizes were analyzed using an ABI
Prism 310 Genetic Analyser (PE Applied Biosystems). The XRCC1 39
UTR microsatellite tandem [AC]n repeat region was amplified using the
following primers (MWG Biotech): XRCC1F 59-CCC GAT GGA TCT
ACA GTT GC-39 and XRCC1R 59-CCC AGG GAG CCT CTT AGA
GT-39. The forward primer was labeled with the fluorophore FAM-6. The
intron tandem [AC]n repeat region in XRCC3 was amplified with
XRCC3F 59-GAC AAT ATG CAT GTA TTA CTT TG-39 and XRCC3R
59-GTG TGC AGT TTA TAT AAG GCA GG-39. The XRCC5 [GAPyA]n
repeat region was amplified using XRCC5F 59-TGT TGC TAT TGT TGT
CTA GC-39 and XRCC5R 59-AAG TCA CTC ACA TGT AAT CC-39.
Both XRCC3R and XRCC5R were labeled with the fluorophore TET.
Multiplex PCR was undertaken in 12.5-ml volumes on an ABI9700 ther-
mal cycler with conditions of 958C for 15 min followed by 25 cycles of
948C for 30 s, 578C for 90 s and 728C for 60 s, with a final 608C hold
for 30 min. PCR was undertaken using a multiplex PCR mix (Qiagen).
Each reaction contained 13 Qiagen Multiplex PCR mix, 0.2 mM of each
primer, and 0.5 ml template DNA. After PCR, fragment analysis was
undertaken on an ABI Prism 310 Genetic Analyser. One microliter of
PCR sample was mixed with 12 ml of deionized formamide and 0.5 ml
of Genescan-500 TAMRA size standard (Applied Biosystems) and de-
natured for 3 min at 948C. Capillary electrophoresis used POP-4 polymer
with a 5-s injection time and 27 min electrophoresis at 608C. Microsat-
ellite allele sizes were converted to repeat lengths based on allele size as
described by Price et al. (13). All genotyping was performed in duplicate.
Statistical Analysis
Statistical analysis was performed by MedCalc 4.0. Allele frequencies
of the different patient groups and the control population were determined
and displayed graphically. Heterozygosities were calculated by dividing
the number of heterozygotes by the total number of individuals. Odds
ratios (ORs) with 95% confidence intervals (95% CI) were calculated for
each microsatellite repeat length to evaluate the association of XRCC1,
XRCC3 and XRCC5 microsatellite genotypes with both clinical radiosen-
sitivity and cancer incidence. Corresponding P values were obtained us-
ing the x2 test. The reference genotype was a pooled sample of individuals
with all repeat numbers, except the one examined. For clinical radiosen-
sitivity, genotypes were compared between radiosensitive patients
(CTC21) and nonradiosensitive patients (CTC0–1). For cancer inci-
dence, genotypes were compared between patients (total population) and
control individuals. Impact of the different external radiotherapy doses,
brachytherapy doses and total doses was evaluated with the Mann-Whit-
ney test. Influence of chemotherapy, surgery and hormone therapy in the
patient population and influence of gender in the control population was
tested using the x2 test.
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1 Cervix yes 45 15 0 32 Cervix no 46 35 3
2 Cervix yes 45 30 0 33 Cervix yes 46 19 0
3 Cervix no 45 20 0 34 Endometrium no 46 19 0
4 Cervix yes 45 19 0 35 Endometrium no 46 19 0
5 Cervix no 45 20 0 36 Endometrium no 46 24 2
6 Cervix no 45 30 0 37 Endometrium no 46 19 2
7 Endometrium no 45 30 0 38 Endometrium no 50 / 5
8 Cervix no 45 20 0 39 Endometrium no 50 15 2
9 Cervix no 45 20 0 40 Cervix yes 50 19 4
10 Endometrium no 45 27 0 41 Endometrium no 50 15 2
11 Endometrium no 45 22 0 42 Endometrium no 50 15 1
12 Cervix no 45 15 2 43 Endometrium no 50 15 0
13 Cervix no 45 25 0 44 Endometrium no 50 15 0
14 Endometrium no 45 20 0 45 Cervix no 50 19 0
15 Cervix no 45 35 2 46 Cervix no 50 15 0
16 Cervix no 46 30 3 47 Endometrium no 50 15 2
17 Cervix no 46 19 0 48 Endometrium no 50 15 2
18 Cervix no 46 15 3 49 Cervix no 50 15 2
19 Cervix no 46 34 3 50 Endometrium no 50 / 0
20 Endometrium no 46 19 2 51 Endometrium no 50 30 1
21 Cervix no 46 24 0 52 Endometrium no 50 15 2
22 Endometrium no 46 34 3 53 Cervix yes 50 14 0
23 Cervix yes 46 30 0 54 Endometrium no 50 19 0
24 Cervix yes 46 20 0 55 Endometrium no 50 15 0
25 Endometrium no 46 19 0 56 Endometrium no 50 15 0
26 Endometrium no 46 19 1 57 Endometrium no 50 15 2
27 Cervix no 46 34 0 58 Endometrium no 50 20 2
28 Endometrium no 46 19 0 59 Endometrium no 50 15 0
29 Endometrium no 46 19 0 60 Cervix no 60 19 0
30 Cervix no 46 19 3 61 Cervix no 60 20 2
31 Endometrium yes 46 19 0 62 Cervix no 60 15 0
RESULTS
An overview of the radiotherapy treatment protocols and
the radiotherapy reactions is given in Table 1. To investi-
gate a possible bias of the treatment protocols, the delivered
radiation doses of both the CTC21 and the CTC31 groups
were compared with the CTC0–1 patient group using a
two-tailed Mann-Whitney test. For the CTC0–1 and
CTC21 groups, no significant difference could be shown
with respect to the external radiotherapy dose (P 5 0.13),
the dose delivered by brachytherapy (P 5 0.74), and the
summation of both doses (P 5 0.72). The comparison of
the CTC0–1 and CTC31 groups resulted in nonsignificant
P values of 0.58, 0.10 and 0.28, respectively. The impact
of the chemotherapy treatment, surgery and hormone ther-
apy on the clinical radiosensitivity in the population was
evaluated by x2 analysis. Therefore, the patient population
was sorted according to the treatment and the CTC grading.
This analysis showed no significant differences in CTC
classification between patients with or without chemother-
apy (P 5 0.27), with or without surgery (P 5 0.91), and
with or without hormone therapy (P 5 0.20).
Figures 1, 2 and 3 show the allele frequencies of the
different microsatellite repeats in XRCC1, XRCC3 and
XRCC5, respectively, for healthy controls, all cancer pa-
tients, nonradiosensitive cancer patients (CTC0–1), and ra-
diosensitive cancer patients (CTC21). The data on the as-
sociation between the number of microsatellite repeats in
XRCC1, XRCC3 and XRCC5 and clinical radiosensitivity
are given in Table 2, while the data on the association be-
tween the microsatellites and cancer incidence are given in
Table 3.
The XRCC1 [AC]n microsatellite was highly polymor-
phic, with between 11 and 22 repeat units and an observed
heterozygosity of 0.74. The most frequently occurring al-
leles were in the range [AC]17 to [AC]19. Allele frequencies
for these repeats were similar in all groups considered. The
smallest observed allele size ([AC]11) had a frequency of
0.047 in healthy controls, 0.073 in all patients, 0.050 in
nonradiosensitive patients, and 0.114 in radiosensitive pa-
tients. Patients with one [AC]11 repeat had a 2.65 times
higher risk of developing adverse radiotherapy reactions.
This result, however, is not statistically significant (P 5
0.325). With this obtained OR of 2.65, a sample size of 160
individuals is needed to reach statistical significance. Allele
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FIG. 1. Allele frequencies of the [AC]n microsatellite in the 39 untranslated region of XRCC1. Number of healthy
controls, 118; number of nonradiosensitive cancer patients, 40; number of clinically radiosensitive cancer patients,
22.
FIG. 2. Allele frequencies of the [AC]n microsatellite in intron 3 of the XRCC3 gene. Number of healthy controls,
118; number of nonradiosensitive cancer patients, 40; number of clinically radiosensitive cancer patients, 22.
frequencies for [AC]21 repeats were 0.034, 0.040, 0.013 and
0.091 for healthy controls, all cancer patients, nonradiosen-
sitive cancer patients, and radiosensitive cancer patients,
respectively. Four patients with one [AC]21 repeat were
found among the 22 clinically radiosensitive patients, while
only one [AC]21 heterozygote was found in the 40 nonra-
diosensitive patients (OR 5 8.67, P 5 0.093). With this
very high OR of 8.67, an increase of the sample size to 80
individuals would be needed to reach statistical signifi-
cance. None of the patients were homozygous for [AC]11
and [AC]21 microsatellite copy numbers; thus we were un-
able to determine whether these alleles act in a recessive
fashion. Comparison of cancer incidence with the presence
of any number of microsatellite repeats in XRCC1 did not
show any distinct association (Table 3).
The XRCC3 [AC]n microsatellite exhibited between 9
and 21 repeat units. The observed heterozygosity for this
repeat was 0.63. The most frequently occurring alleles were
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FIG. 3. Allele frequencies of the [GAPyA]n microsatellite 120 kb from the XRCC5 gene. A small proportion of
the alleles were extended by two nucleotides, resulting in [GAPyA]1412, [GAPyA]1512, [GAPyA]1612, [GAPyA]1712
and [GAPyA]1912 repeats. Number of healthy controls, 118; number of nonradiosensitive cancer patients, 40; number
of clinically radiosensitive cancer patients, 22.
TABLE 2




11 17 18 19 20 21
Nonradiosensitive patients 4 (4/0) 18 (13/5) 20 (11/9) 17 (14/3) 3 (3/0) 1 (1/0)
Radiosensitive patients 5 (5/0) 11 (10/1) 12 (10/2) 8 (8/0) 1 (1/0) 4 (4/0)
Odds ratio 2.65 1.22 1.20 0.77 0.59 8.67
95% CI 0.63–11.13 0.43–3.47 0.42–3.41 0.26–2.26 0.06–6.01 0.90–83.17
XRCC3b 14 15 16 17 20 21
Nonradiosensitive patients 24 (20/4) 3 (3/0) 29 (18/11) 2 (2/0) 3 (3/0) 3 (3/0)
Radiosensitive patients 13 (11/2) 1 (1/0) 17 (10/7) 3 (3/0) 1 (1/0) 0
Odds ratio 0.96 0.59 1.29 3.00 0.59 —
95% CI 0.33–2.78 0.06–6.01 0.38–4.35 0.46–19.51 0.06–6.01 —
XRCC5c 14 1 2 15 15 1 2 16 16 1 2 17
Nonradiosensitive patients 1 (1/0) 22 (17/5) 4 (3/1) 24 (19/5) 1 (0/1) 12 (12/0)
Radiosensitive patients 0 12 (9/3) 4 (3/1) 12 (8/4) 1 (1/0) 6 (5/1)
Odds ratio — 0.98 2.00 0.80 1.86 0.88
95% CI — 0.35–2.79 0.45–8.94 0.28–2.29 0.11–31.22 0.28–2.78
Notes. The number of individuals carrying at least one allele is given (with number of heterozygous/homozygous individuals indicated in parentheses).
Odds ratios, with 95% CI, for risk of radiosensitivity are shown for nonradiosensitive patients (n 5 40) compared to radiosensitive patients (n 5 22).
a Does not include [AC]22 repeats for which only one individual was seen.
b Does not include [AC]9, [AC]13, [AC]18, [AC]19 repeats for which only one individual each was seen.
c Does not include [GAPyA]17 1 2, [GAPyA]19, [GAPyA]19 1 2 for which only one individual each was seen and [GAPyA]18 for which only two
individuals were seen.
[AC]14 and [AC]16. The largest allele, [AC]21, was found at
a frequency of 0.034 in controls, 0.024 in all cancer pa-
tients, 0.038 in nonradiosensitive cancer patients, and 0 in
clinically radiosensitive cancer patients. Accordingly, no
measure of association with radiosensitivity could be un-
dertaken. Patients carrying one [AC]17 repeat had a three
times higher risk of developing normal-tissue reactions af-
ter radiotherapy in comparison with patients having any
other number of repeats, although this is not statistically
significant (P 5 0.479). None of the patients were homo-
zygous for the [AC]17 repeat (Table 2). A borderline sig-
nificant positive association was found between the pres-
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TABLE 3
Association between Microsatellite Repeat Number in XRCC1, XRCC3 and XRCC5 and Cancer Incidence
XRCC1a
Number of repeats
11 17 18 19 20 21
Controls 11 (11/0) 67 (60/7) 74 (59/15) 36 (31/5) 12 (12/0) 8 (8/0)
Patients 9 (9/0) 29 (23/6) 32 (21/11) 25 (22/3) 4 (4/0) 5 (5/0)
Odds ratio 1.65 0.67 0.63 1.54 0.61 1.21
95% CI 0.64–4.23 0.36–1.24 0.34–1.18 0.81–2.92 0.19–1.97 0.38–3.86
XRCC3b 14 15 16 17 20 21
Controls 76 (54/22) 11 (9/2) 77 (59/18) 5 (4/1) 13 (13/0) 8 (8/0)
Patients 37 (31/6) 4 (4/0) 46 (28/18) 5 (5/0) 4 (4/0) 3 (3/0)
Odds ratio 0.82 0.67 1.53 1.98 0.56 0.70
95% CI 0.43–1.54 0.20–2.20 0.77–3.03 0.55–7.13 0.17–1.79 0.18–2.74
XRCC5c 14 1 2 15 15 1 2 16 16 1 2 17
Controls 1 (1/0) 80 (64/16) 10 (6/4) 72 (64/8) 12 (12/0) 31 (30/1)
Patients 1 (1/0) 34 (26/8) 8 (6/2) 36 (27/9) 2 (1/1) 18 (17/1)
Odds ratio 1.92 0.58 1.60 0.88 0.29 1.17
95% CI 0.12–31.20 0.31–1.09 0.60–4.29 0.47–1.65 0.06–1.36 0.59–2.33
Notes. The number of individuals carrying at least one allele is given (with number of heterozygous/homozygous individuals indicated in parentheses).
Odds ratios, with 95% CI, for risk of cancer are shown for healthy controls (n 5 118) compared to cancer patients (n 5 62).
a Does not include [AC]22 repeats for which only one individual was seen.
b Does not include [AC]9, [AC]13, [AC]18, [AC]19 repeats for which only one individual each was seen.
c Does not include [GAPyA]17 1 2, [GAPyA]19, [GAPyA]19 1 2 for which only one individual each was seen and [GAPyA]18 for which only two
individuals were seen.
ence of two [AC]16 repeats and cancer incidence (OR 5
2.56, P 5 0.055). Other [AC] repeats did not show any
significant association with cancer incidence.
The XRCC5 [GAPyA]n tetranucleotide microsatellite was
polymorphic, with repeat units from 14 to 19. The observed
heterozygosity for this repeat was 0.63. A small proportion
of the alleles were extended by two nucleotides, resulting
in [GAPyA]1412, [GAPyA]1512, [GAPyA]1612, [GAPyA]1712
and [GAPyA]1912 repeats. The most frequent alleles were
[GAPyA]15 and [GAPyA]16. The rarest alleles were the
smallest and the largest ([GAPyA]1412, [GAPyA]1712,
[GAPyA]18, [GAPyA]19, [GAPyA]1912), representing to-
gether 0.8, 4, 6.3 and 0% in healthy controls, all cancer
patients, nonradiosensitive cancer patients, and radiosensi-
tive cancer patients, respectively (Fig. 3). Statistical anal-
ysis of clinical radiosensitivity or cancer incidence with the
presence of any number of microsatellite repeats in XRCC5
did not show any significant association.
DISCUSSION
This study investigated the association between poly-
morphic microsatellites in the DNA repair genes XRCC1,
XRCC3 and XRCC5 and the risk of developing normal-
tissue reactions after radiotherapy treatment. Therefore, we
have screened for these microsatellites in patients with can-
cer of the cervix or endometrium who received radiother-
apy. To determine the overall microsatellite frequency in a
Belgian population and to assess the correlation of these
microsatellites with gynecological tumors, a control popu-
lation consisting of healthy individuals was also screened.
The microsatellites examined are located in different ge-
nomic contexts: The XRCC1 microsatellite occurs in the
39UTR of the gene, the XRCC3 microsatellite is intronic,
and the XRCC5 microsatellite is located 120 kb from the
gene. The microsatellites within XRCC1 and XRCC3 have
previously been suggested to be associated with radiosen-
sitivity and cancer incidence (13). The microsatellite in
XRCC5 was included based on the involvement of the
XRCC5 gene in the NHEJ repair pathway.
The overall microsatellite frequencies and distribution of
repeat lengths in a healthy Belgian population were similar
to those reported previously in studies of UK newborns and
retired UK radiation workers (25, 26) and in an Australian
twin study for XRCC3 and XRCC5 (27).
In 1997, Price et al. (13) reported a highly significant
association between clinical radiosensitivity and rare mi-
crosatellites in XRCC1 and XRCC3 in a population of 19
cancer patients. In their study, rare microsatellites were al-
leles with less than 12 or more than 23 repeats for XRCC1,
alleles with more than 20 repeats for XRCC3, and alleles
with less than 14 or more than 18 repeats for XRCC5. All
other microsatellite allele sizes were classified as common
repeats. In this study we found a positive correlation be-
tween patients with [AC]11 repeats and patients with [AC]21
repeats in XRCC1 and the risk of developing adverse ra-
diotherapy reactions, but these results were not statistically
significant for both repeat numbers (P 5 0.325 and P 5
0.093, respectively). Alleles with more than 23 [AC] re-
peats were not present in the patient population or in the
control population. Large XRCC3 alleles ([AC]20 and
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[AC]21 repeats) did not correlate with clinical radiosensitiv-
ity, while XRCC3 [AC]17 repeats were slightly more com-
mon in patients with adverse radiotherapy reactions (P 5
0.479). For XRCC5, no examples of rare (#14 or $18)
repeat lengths were identified in the clinically radiosensitive
patient group. Accordingly, no measure of association with
radiosensitivity could be undertaken. For the other more
common repeat lengths, we found no association with clin-
ical radiosensitivity.
Furthermore, we could not demonstrate an association
between the rare microsatellite alleles considered and can-
cer incidence. However, a weak correlation was found be-
tween XRCC3 [AC]16 homozygotes and cancer incidence
(P 5 0.055). Subdividing the patient group into cervical
and endometrial cancer cases, the positive association with
the XRCC3 [AC]16 repeat is retrieved only for endometrial
cancer (P 5 0.057).
Although we found no significant association between
the rare microsatellite alleles considered and clinical radio-
sensitivity or cancer incidence, the microsatellites could af-
fect radiosensitivity or cancer in a recessive manner. Be-
cause of the small numbers of individuals homozygous for
the rare microsatellite repeats, we are unable to test this
hypothesis. For other microsatellite repeat lengths where
sufficient variant homozygotes were detected, we found
(XRCC3 [AC]16 excluded) no evidence for a recessive ac-
tion of these polymorphisms. We have consequently as-
sumed dominance and treated the data accordingly.
For this study, radiosensitivity classification of the pa-
tients is based on grading of the normal-tissue reactions to
the radiotherapy according to the CTCAE scale (23). Pa-
tients with intermediate but distinct radiotherapy reactions
(CTC2) were pooled with patients with severe (CTC3) to
life-threatening (CTC4/5) radiotherapy reactions. To assess
possible differences in genotypes between the more severe
radiosensitive individuals (CTC3/4/5), the intermediate ra-
diosensitive patients (CTC2) and the nonradiosensitive pa-
tients (CTC0–1), we performed analyses of CTC3/4/5 (n 5
8) compared to CTC0–1 (n 5 40) and CTC2 (n 5 14)
compared to CTC0–1 (n 5 40) analysis. The outcome of
these analyses showed similar associations with the initial
analysis (results not shown). Furthermore, the supplemental
analysis showed that the XRCC1 [AC]11 repeat occurred 2.3
times more frequently in the CTC2 patient group than in
the CTC3/4/5 patient group. On the other hand, the XRCC1
[AC]21 repeat was present more often in the CTC3/4/5 pa-
tient group, resulting in an odds ratio of 13 compared the
nonradiosensitive patient group (CTC0–1). Due to the low
frequency of this microsatellite repeat and the small number
of patients with very severe radiotherapy reactions, no sta-
tistical significance for this effect was reached (P 5 0.110).
Although not statistically significant, higher odds ratios
were obtained for XRCC1 [AC]11 and XRCC1 [AC]21 alleles
in radiosensitive patients. Therefore, we are not able to
completely reject the hypothesis that these small and large
rare alleles may be associated with adverse radiotherapy
outcome. The strongly positive associations found by Price
et al. between XRCC1 [AC]24 and XRCC3 [AC]20 repeats
and clinical radiosensitivity were not found in this study,
nor could we show significant associations between rare
microsatellite repeats and cancer incidence. These discrep-
ancies could be due to the fact that the two studies are
based on different cancer populations and studied different
radiosensitivity end points. The fact that both studies could
not demonstrate an association between the XRCC5 micro-
satellite, clinical radiosensitivity and cancer incidence could
be explained by the distant location of the microsatellite
considered from the gene.
Due to the highly polymorphic nature of the loci consid-
ered, in the future, larger studies with larger numbers ra-
diosensitive cases in a multicenter setting are needed to
clarify the involvement of rare polymorphic microsatellites
in XRCC1 and XRCC3 DNA repair genes in either clinical
radiosensitivity or cancer incidence.
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